BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Artemis II astronauts race to set a new distance record from Earth and behold the moon's far side - 2Your big brain makes you human – count your neurons when you count your blessings
- 3Every year, she thanks the trooper for the arrest that led to her sobriety
- 4Revvity says it will exceed 2025 profit forecast range
- 5Reports: Germany plans expansion of foreign intelligence powers
- It May Take a Year to Restore Abu Dhabi Aluminum Output, EGA Says
- Tech Patterns 2023: 12 Advancements to Keep an eye Out For
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump
- Nations for Youngsters to Visit
- She just became the first wheelchair user to travel to space
- Astronomers detect black hole blasting winds at incredible speeds
- How food assistance programs can feed families and nourish their dignity
- Who plays Moana in the live-action remake? What to know about Catherine Lagaʻaia.
